Inflammatory hepatocellular adenomas are benign liver tumours defined by the presence of inflammatory infiltrates and by the increased expression of inflammatory proteins in tumour hepatocytes 1,2 . Here we show a marked activation of the interleukin (IL)-6 signalling pathway in this tumour type; sequencing candidate genes pinpointed this response to somatic gain-of-function mutations in the IL6ST gene, which encodes the signalling co-receptor gp130. Indeed, 60% of inflammatory hepatocellular adenomas harbour small in-frame deletions that target the binding site of gp130 for IL-6, and expression of four different gp130 mutants in hepatocellular cells activates signal transducer and activator of transcription 3 (STAT3) in the absence of ligand. Furthermore, analysis of hepatocellular carcinomas revealed that rare gp130 alterations are always accompanied by b-catenin-activating mutations, suggesting a cooperative effect of these signalling pathways in the malignant conversion of hepatocytes. The recurrent gain-offunction gp130 mutations in these human hepatocellular adenomas fully explains activation of the acute inflammatory phase observed in tumourous hepatocytes, and suggests that similar alterations may occur in other inflammatory epithelial tumours with STAT3 activation.
Several recent studies have shown STAT3 activation in epithelial tumours, underscoring the importance of IL-6 signalling and the inflammatory response in tumorigenesis and providing an opportunity for therapeutic intervention 3 . However, the mechanisms that provoke sustained STAT3 activation in tumours are largely unresolved. To define the interaction between the inflammatory response and carcinogenesis in liver tumours, we assessed inflammatory hepatocellular adenomas (IHCAs), benign tumours predominately found in women and frequently associated with obesity and alcohol use 1, 2 . Tumour hepatocytes of these adenomas express increased levels of serum amyloid A (SAA) and C-reactive proteins (CRP), two members of the acute-phase inflammatory response, whereas SAA and CRP are not expressed in inflammatory cells, Kupffer cells or other sinusoidal cells in IHCAs (Fig. 1a, Supplementary Fig. 1 and ref. 1 ). Inflammatory infiltrates were largely localized to arterial vessels, but were also found within the sinusoidal lumens of IHCAs. Here, CD45
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1 T lymphocytes (CD4:CD8, 2:1) were intermingled with less numerous CD20
1
CD79A
1 B cells, some plasma cells and a few polymorphonuclear cells; no CD30
1 lymphocytes nor CD56 1 or CD57 1 natural killer cells were observed. In addition, CD68
1 histiocytes were present in infiltrates, and prominent Kupffer cells were present in sinusoidal lumens ( Supplementary  Fig. 1 ). Overall, inflammatory infiltrates observed in IHCAs were highly polymorphous.
To resolve the underlying pathogenesis of these inflammatory lesions, a genome-wide transcriptome analysis of four IHCAs was compared to four normal liver tissue samples. Among the 285 genes significantly overexpressed in IHCAs (Supplementary Table 1) , gene ontology analysis identified a strong enrichment for genes associated with inflammation and the immune response, accounting for 40% of the overall ontology terms significantly enriched (Supplementary  Table 2 ). High levels of significance were found for genes involved in 'antigen processing and presentation of peptide antigen' (P 5 2.10
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) and 'regulation of the Janus kinase (JAK)-STAT cascade' (P 5 10 25 ; Supplementary Table 2) . We confirmed this inflammatory signature in an additional 14 IHCAs with a clear activation of the acute-phase inflammatory response affecting both type-1 and type-2 acute-phase genes (Fig. 1b, c and Supplementary Table 3) . Consistent with the known roles of IL-6 and JAK-STAT signalling in the acute-phase response 4, 5 , STAT3 messenger RNA and protein were significantly increased in IHCAs (Fig. 1b, c) . IHCAs also overexpressed several effectors of type-1 and type-2 interferon signalling pathways (for example JAK2, STAT1 and STAT2) and their downstream targets (Fig. 1b, c) . Collectively, these data suggest that IL-6 and interferon signalling are the main inflammatory pathways activated in IHCAs (Fig. 1d) .
Because IL-6 was not overexpressed in IHCAs and the inflammatory response was restricted to tumour hepatocytes (Fig. 1a) , we reasoned that somatic genetic mutation(s) might account for activation of IL-6 receptor signalling in IHCAs. We selected IL6ST as a candidate gene because it encoded the cell surface signalling receptor gp130 shared by at least six different cytokines including IL-6, IL-11, LIF, OSM, CNTF and CT-1 (also known as CTF1; refs 4, 6). We sequenced the entire gp130 coding region in 43 IHCAs and 33 noninflammatory hepatocellular adenomas. Twenty-six mutations in gp130 were identified specifically in 60% (26 out of 43) of IHCAs, including 16 unique, small in-frame deletions and one 33-base-pair in-frame duplication in exon 6 ( Fig. 2a and Table 1 ). Notably, all IL6ST mutations were found in IHCAs and all were of somatic origin, because they were not observed in adjacent normal liver tissues. In all cases, IL6ST mutations were monoallelic, and IHCAs with these mutations expressed both the wild-type and mutated alleles at comparable levels, as judged by sequencing polymerase chain reaction with reverse transcription (RT-PCR) products of IL6ST mRNA ( Supplementary  Fig. 2 ).
Binding of IL-6 to its cognate receptor gp80 (encoded by IL6R) induces formation of a high-affinity ternary hexameric complex consisting of two molecules each of IL-6, IL-6R and gp130 (refs 7, 8) . gp130 engagement then activates JAK-Tyk tyrosine kinases and the STAT family of transcription factors [9] [10] [11] . The consequences of the IL6ST in-frame deletions observed in IHCAs included the removal of 1 to 26 amino acids neighbouring the IL-6/IL-6R binding site (also known as cytokine-receptor homology region, CHR, E-F loop) located in D2 domain of gp130 (Fig. 2a) . We modelled the different deletions and the duplication in the known crystal structure of the wild-type IL-6-IL-6R-gp130 ternary complex (Protein Data Bank, PDB: 1P9M) 7 . All of these mutations are predicted to disrupt key residues involved in the gp130-IL-6 interface. Specifically, the most frequent alterations target residues 186-191, which direct the gp130-IL-6 interaction, whereas the remaining deletions and duplication affect the other two loops that contribute to gp130-IL-6 interactions (Fig. 2b) . Therefore, the gp130-IL-6 interface is targeted in IHCAs.
To investigate possible functional consequences of these gp130 mutations, we tested the effects of enforced expression of two frequent deletions (S187-Y190del and Y186-Y190del) and two infrequent mutants (V184-Y186del, S187A and K173-D177del) in Hep3B cells, a hepatocellular carcinoma line that activates the acute inflammatory phase after IL-6 treatment 12 . In the absence of IL-6 ligand and serum, overexpression of wild-type gp130 alone was not sufficient to activate STAT3 and the downstream acute-phase inflammatory genes ( Fig. 3 and refs 7, 13) . In contrast, all gp130 IHCA mutants activated an acute-phase inflammatory response and induced typical targets of this response, including CRP, SAA2, SPINK1 and FBG (Fig. 3a, c) . Furthermore, as observed in IHCAs, all of these gp130 mutants induced the expression of SOCS3, which normally serves to harness cytokine signalling (Fig. 3a) . Mutant gp130 S187-Y190del was constitutively tyrosine phosphorylated and the activity of STAT3 was clearly increased in gp130 S187-Y190del-expressing Hep3B cells (Fig. 3b) . Similarly, immunohistochemical analyses of IHCAs demonstrated marked increases in nuclear STAT3 phosphorylated at Tyr 705 ( Supplementary Fig. 4e, f) . Finally, IL-6 augmented the induction of CRP in gp130 S187-Y190del-expressing cells, but mutant receptors were not hypersensitive to low doses of IL-6 ( Fig. 3d) . Therefore, gp130 mutants are constitutively active, and they activate STAT3 and inflammatory response genes in the absence of IL-6.
A critical step in the activation of intracellular signalling after IL-6 binding on gp130 is the formation of a hexameric structure that juxtaposes the membrane-proximal domains of two gp130 molecules at the cell surface 7, 14, 15 . Using co-immunoprecipitation, we showed that the gp130 S187-Y190del IHCA mutant was able to homodimerize or heterodimerize with wild-type gp130 independently of IL-6, whereas wild-type gp130 cannot homodimerize (Fig. 3f) . Homodimerization of gp130 in the absence of ligand has also been described previously for two other gp130 mutants, Y190FV-to-AAA and Y190A (ref. 16 ). Moreover, overexpression of wild-type gp130 impaired the activity of the mutant gp130 S187-Y190del in a dosedependent manner (Fig. 3e) ; therefore, mutant gp130 activity seems to be driven by its homodimerization, which can be competed for by the wild-type protein. Interestingly, it has recently been shown using a reverse genetic approach in mice that IL-11 promotes chronic gastric inflammation and associated tumorigenesis mediated by gp130 and STAT3 activation 17 . In IHCAs, we also found significant increases Genes validated by qRT-PCR are underlined (IHCA, n 5 14; NTL, n 5 6); others were extracted from the microarray analysis (IHCA, n 5 4; NTL, n 5 4). APRE (acute phase response element), GAS (interferon-c-activated site), IL-6Ra (also known as gp80 or IL-6R), IL-6-RE (interleukin 6 response element), ISRE (interferon-sensitive response element).
(sixfold) in the levels of IL11 mRNA (P , 0.01), which may serve to amplify gp130-IL-6 signalling, despite a modest decrease in the expression of its specific receptor (IL11RA; Supplementary Fig. 5a ). However, in mutant gp130-expressing Hep3B cells IL11 was not induced ( Supplementary Fig. 5b ), suggesting that an increase of IL11 in IHCAs in vivo may occur through secondary effects.
Relationships between activation of IL-6 signalling and hepatic tumorigenesis have also been suggested from studies in mice, in which transgenic animals that overexpress both IL-6 and IL-6R in hepatocytes develop large liver adenomas 18 . Furthermore, in knockin mice expressing gp130(Y757) mutant, gastric inflammation and subsequent carcinoma development result from STAT3 activation [19] [20] [21] . The IL-6 pathway is also known to activate SHP-2-RAS-ERK signalling 22 . However, in humans, STAT3 activation is a clear hallmark of gp130-mutated IHCAs, phosphorylated ERK1 and ERK2
Ligand-binding site . IHCA deletions 173-177 and 215 (labelled in red) are also predicted to disrupt the IL-6-gp130 interface. The numbering of residues corresponds to the IL6ST complementary DNA, which has 22 additional amino-terminal residues compared with the polypeptide chain due to the peptide signal. . f, Flag-and Myctagged constructs expressing either the WT or the mutant DS gp130 were cotransfected (1:1) into Hep3B cells. gp130 dimer formation was detected after immunoprecipitation using the anti-flag antibody, followed by western blot (WB) analysis with the anti-Myc and anti-Flag antibodies. Shown is one representative of three independent experiments. *, ** and *** indicate differences between groups at P , 0.05, P , 0.01 and P , 0.001, respectively (two-tailed t-test).
(phospho-ERK1/2) was only detected in 50% of these tumours ( Supplementary Fig. 6a) , and phospho-ERK1/2 was not observed in Hep3B cells overexpressing mutant gp130 (Supplementary Fig.  6b ). Thus, in contrast to STAT3 activation, activation of the SHP-2-RAS-ERK pathway does not seem to contribute to all IHCAs. Surprisingly, type-1 and type-2 interferon targets are overexpressed in gp130-mutated IHCAs. Their aberrant activation here might be due to gp130-mediated STAT1 and STAT2 activation and inefficient negative feedback by SOCS3, which is thought to prevent activation of type-2 interferon genes under physiological conditions 23 . Interestingly, the targets in gp130-mutated IHCAs include HIF1A (encoding hypoxia-inducible factor-1a), which may contribute to vascular endothelial growth factor (VEGF) overexpression and the 'telangiectatic' phenotype of IHCAs (Fig. 1b, c) 1,2,24 . Furthermore, the inflammatory infiltrate that is a hallmark of IHCAs may reflect the robust induction (,110-fold) of CCL20 observed in all IHCAs (Fig. 1b) . Specifically, CCL20 is a chemokine that interacts with CCR6 and that directs chemoattraction of a wide spectrum of immune cells including dendritic cells and B and T lymphocytes 25 , and such a scenario could direct or augment the inflammatory response seen in IHCAs.
To investigate the possible interaction and cooperation of gp130 activation with other pathways altered in hepatocellular adenoma, we searched in the same series of 76 adenomas for CTNNB1 (encoding b-catenin) and HNF1A (encoding hepatocyte nuclear factor 1a) mutations, two genetic alterations frequently associated with hepatocellular adenomas (HCAs) 2, 26, 27 . HNF1a inactivation (22 cases) and gp130 activation (26 cases) were mutually exclusive in HCAs (P , 10
24 , Fisher exact test; Supplementary Table 4 ). In contrast, b-catenin-activating mutations were found in 12 adenomas, and half of these had associated gp130 mutations. For two IHCAs associated with a malignant transformation to carcinoma, both activating gp130 and b-catenin mutations were found (cases 469 and 786; Supplementary Table 4 ). In one of these cases we were able to genotype the hepatocellular carcinoma (HCC), and this harboured the same mutations in CTNNB1 and IL6ST as the corresponding IHCA. In contrast, no cases of malignant transformation were observed in gp130-mutated IHCAs without a b-catenin mutation (P 5 0.05, twotailed Fisher exact test). When we sequenced IL6ST exon 6 in 111 HCCs lacking a known history of IHCAs 28 , only two cases were mutated. Interestingly, these tumours were compatible with a malignant transformation of a non-diagnosed IHCA because both mutated HCCs had inflammatory infiltrates; they harboured b-catenin-activating mutations and developed in non-cirrhotic liver (Supplementary Table 4 ). Collectively, these findings suggest cooperation between the IL-6 and b-catenin pathways in the malignant transformation of IHCAs.
IL6ST mutations were identified in 60% of IHCAs. The remaining IHCAs were, however, similar in their expression profiles to IL6ST-mutated IHCAs (Supplementary Fig. 3 ) and, accordingly, activated nuclear phospho-STAT3 was also found in all non-mutated IHCAs tested ( Supplementary Fig. 4f) . Sequencing of the functional domains of three gp130 co-receptors (IL6R, LIFR and OSMR), of the functional domains of three transducing proteins (JAK2, JAK1 and TYK2) and of the coding sequence of SOCS3 failed to identify mutations in gp130-non-mutated IHCAs. Moreover, these tumours lacked mutations in the exons or intron-exon boundaries of IL6ST, and IL6ST mRNA levels were comparable to those expressed in normal hepatocytes ( Supplementary Fig. 4a ). Finally, no gain of chromosome 5q copy number at the IL6ST locus was observed using comparative genomic hybridization using single nucleotide polymorphism genotyping (CGH-SNP) experiments in gp130-mutated and -non-mutated IHCAs (data not shown). However, by western blotting and immunohistochemistry we found that most IHCA cases overexpressed gp130 protein ( Supplementary Fig. 4b-d) , suggesting that the translation or turnover of gp130 is affected in both gp130-non-mutated and -mutated tumours. Therefore, gp130 overexpression and STAT3 activation are related to gp130 activating mutation in 60% of the IHCAs, whereas, in the non-mutated cases, the mechanism of STAT3 activation remains to be defined. Here, for example, activation may reflect mutations in a regulatory protein(s) that controls gp130 stabilization, or may be due to alterations in factors that control its translation.
The present findings reveal that STAT3 activation and the inflammatory phenotype in benign liver tumours can occur through gainof-function somatic mutations in gp130. To our knowledge, this is the first identification of somatic mutation of gp130 in tumours, and our findings define gp130 as an oncogene with involvement in benign human tumours. Our findings also underscore the important role of inflammatory response in hepatocellular tumorigenesis and are in accordance with a recent study demonstrating that IL-6 promotes liver tumour onset in mice 29 . Importantly, our studies also suggest that cooperating mutations of the WNT-b-catenin and IL-6-STAT pathways in human liver tumours contribute to the occurrence of inflammatory hepatocellular carcinomas that develop in the absence of cirrhosis. More broadly, these findings indicate that this novel mechanism for activation of the IL-6 signalling pathway should be interrogated in other human tumours, particularly those with an inflammatory phenotype and STAT3 activation, a hallmark of many epithelial tumours.
METHODS SUMMARY
All tumours and corresponding non-tumour liver tissues were frozen after surgical resection. These tumours were clinically and genetically characterized; they were previously included in genetic and phenotypic studies (Supplementary  Table 4 and refs 1, 2, 28). The study was approved by the local Ethics Committee (Paris Saint-Louis), and informed consent was obtained in accordance with French legislation. Transcriptional profiling experiments were performed using Affymetrix oligonucleotide GeneChips HG-U133A. Quantitative (q)RT-PCR was performed as described 30 using pre-designed primers and probe sets from Applied Biosystems (provided in Supplementary Table 5 ). In all cases the somatic origin of the mutation found in a tumour was verified by sequencing the corresponding adjacent, normal liver sample. In Hep3B cell experiments, all qRT-PCRs, luciferase assays and western blotting experiments were performed two days after transfection and after 6 h of serum starvation.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
